111 Capital Raises Holdings in Hologic, Inc. $HOLX

Key Points

• 111 Capital significantly increased its stake in Hologic, Inc. by 129.1%, owning 16,085 shares valued at $1,048,000 as per the latest SEC filing.
• Hologic's stock has a current market capitalization of $15.17 billion and reported a 12-month revenue increase of 1.2% year-over-year, with a quarterly EPS of $1.08, exceeding estimates.
• Several institutional investors, including Cromwell Holdings and Mirae Asset Global Investments, also raised their holdings in Hologic during the second quarter, reflecting increased institutional interest in the stock.

111 Capital boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 129.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,085 shares of the medical equipment provider's stock after acquiring an additional 9,064 shares during the quarter. 111 Capital's holdings in Hologic were worth $1,048,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Cromwell Holdings LLC boosted its holdings in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 436 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Hologic by 9.2% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 33,089 shares of the medical equipment provider's stock worth $2,156,000 after buying an additional 2,784 shares during the last quarter. J. Safra Sarasin Holding AG increased its stake in shares of Hologic by 55.3% during the second quarter. J. Safra Sarasin Holding AG now owns 12,280 shares of the medical equipment provider's stock valued at $800,000 after buying an additional 4,371 shares during the period. PFG Investments LLC raised its holdings in shares of Hologic by 6.7% during the second quarter. PFG Investments LLC now owns 8,011 shares of the medical equipment provider's stock valued at $522,000 after acquiring an additional 500 shares in the last quarter. Finally, Greenleaf Trust raised its holdings in shares of Hologic by 5.1% during the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock valued at $233,000 after acquiring an additional 173 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Up 0.5%

Hologic stock opened at $68.22 on Friday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The firm has a market cap of $15.17 billion, a price-to-earnings ratio of 28.31, a PEG ratio of 2.34 and a beta of 0.63. The stock has a fifty day simple moving average of $66.97 and a two-hundred day simple moving average of $63.09.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the company posted $1.06 earnings per share. Hologic's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.88% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HOLX shares. Argus upped their target price on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a report on Friday, September 19th. Morgan Stanley upped their target price on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Stephens restated an "overweight" rating and set a $78.00 target price on shares of Hologic in a report on Thursday, September 18th. Evercore ISI upped their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Finally, Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.